ArticleThe Lancet. Rheumatology2021

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.

Matthias B Moor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.